| Date | Title | Description |
| 23.09.2024 | Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi | SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with ... |
| 19.09.2022 | Ventyx Biosciences closes a $176.6M PIPE deal to fund the clinical development of new assets and support the company | - |
| 19.09.2022 | Ventyx seeks to rack up $176M+ in its latest move as the market become bullish on TYK2 | California-based biotech Ventyx Biosciences has managed to snap up quite a bit of cash since emerging last year, and its latest move will hope to give the company another nine-figure boost.
On Monday, Ventyx announced that i... |
| 22.10.2021 | Ventyx BioSciences opens up their IPO at a value of $151.56M | - |
| 14.10.2021 | Ventyx BioSciences Raises a Series B Round of $51M that better positions the company and allows for further development of their products | - |
| 13.10.2021 | Ventyx BioSciences Raises a Series B Round of $51M that better positions the company and allows for further development of their products | - |
| 11.10.2021 | Ventyx BioSciences Raises a Series B Round of $51M that better positions the company and allows for further development of their products | - |
| 10.10.2021 | Ventyx BioSciences Raises a Series B Round of $51M that better positions the company and allows for further development of their products | - |
| 09.10.2021 | Ventyx BioSciences Raises a Series B Round of $51M that better positions the company and allows for further development of their products | - |
| 08.10.2021 | Ventyx BioSciences Raises a Series B Round of $51M that better positions the company and allows for further development of their products | - |
| 07.10.2021 | Ventyx BioSciences Raises a Series B Round of $51M that better positions the company and allows for further development of their products | - |
| 06.10.2021 | Digital health news, funding roundup in the prior week; October 4 | Amazon expanding senior health leaders; Mayo Clinic and Lisa Health team up for menopause initiative
Amazon's getting more serious about healthcare. Amazon's 10 most recent healthcare job openings include: Manager of revenue cycle for Amazo... |
| 03.10.2021 | Ventyx BioSciences Raises a Series B Round of $51M that better positions the company and allows for further development of their products | - |
| 02.10.2021 | Ventyx BioSciences Raises a Series B Round of $51M that better positions the company and allows for further development of their products | - |
| 20.09.2021 | Ventyx Biosciences snags $51M, hires new CMO from Horizon Therapeutics | Ventyx Biosciences is the amalgamation of three biotechs, and now it's bringing together three autoimmune experts and another $51 million to back their work.
RELATED: Ventyx bags $114M to test drugs against hot immunology targets
Drappa's h... |
| 20.09.2021 | Ventyx Biosciences Announces Key Appointments and Closing of $51.0 Million Series B Convertible Preferred Stock Financing Round | - |
| 20.09.2021 | Daily funding roundup - September 20th, 2021 | TrueLayer raised $130M; Clickhouse landed $50M; Near Space Labs secured $13M
Fivetran: Fivetran is a Oakland, Ca.-based data connectivity startup. Fivetran has raised $565 million investment in Series D funding led by earlier investor Andre... |
| 20.09.2021 | Ventyx Biosciences Announces Key Appointments and Closing of $51.0 Million Series B Convertible Preferred Stock Financing Round | Drs. Sheila Gujrathi (Executive Chair), Jörn Drappa (Chief Medical Officer) and Luisa Salter-Cid (Chair of the Scientific Advisory Board) bring decades of development experience in autoimmune diseasesWilliam White (Independent Director) str... |
| 20.09.2021 | Ventyx Biosciences Announces Key Appointments and Closing of $51.0 Million Series B Convertible Preferred Stock Financing Round | Drs. Sheila Gujrathi (Executive Chair), Jörn Drappa (Chief Medical Officer) and Luisa Salter-Cid (Chair of the Scientific Advisory Board) bring decades of development experience in autoimmune diseases
William White (Independent Director) st... |
| 20.09.2021 | Ventyx Biosciences snags $51M, hires new CMO from Horizon Therapeutics | Ventyx Biosciences is the amalgamation of three biotechs, and now it's bringing together three autoimmune experts and another $51 million to back their work.
The Encinitas, California-based biotech secured the series B convertible preferred... |
| 20.09.2021 | Ventyx BioSciences Raises a Series B Round of $51M that better positions the company and allows for further development of their products | - |
| 10.03.2021 | Ventyx Biosciences secures $114M | Ventyx Biosciences has raised $114 million in a round led by VenBio Partners, with participation from Third Point, RTW Investments and OrbiMed, among others. The Encinitas, Calif.-based company is developing therapeutics to treat inflammato... |
| 09.03.2021 | Ventyx Biosciences has raised $114M to advance their broad pipeline of potent and selective small-molecule drug candidates to treat inflammatory diseases and autoimmune disorders | - |
| 09.03.2021 | Ventyx Biosciences Raises $114M in Funding | Ventyx Biosciences, an Encinitas, California-based clinical-stage biotechnology company advancing a broad pipeline of potent and selective small-molecule drug candidates to treat inflammatory diseases and autoimmune disorders, raised $114m ... |
| 09.03.2021 | Ventyx Biosciences Raises $114 Million Financing led by venBio Partners to Advance Diverse Pipeline of Immunology Programs | |
| 09.03.2021 | Ventyx bags $114M to test drugs against hot immunology targets | Ventyx Biosciences has exited stealth mode with $114 million to fund development of immunology programs. The venBio Partners-led financing will support a pipeline led by a S1P1R modulator that is in clinical development as a treatment for i... |
| 09.03.2021 | Ventyx Biosciences Raises $114 Million Financing led by venBio Partners to Advance Diverse Pipeline of Immunology Programs | - |
| 09.03.2021 | Ventyx bags $114M to test drugs against hot immunology targets | Ventyx Biosciences has exited stealth mode with $114 million to fund development of immunology programs. The venBio Partners-led financing will support a pipeline led by a S1P1R modulator that is in clinical development as a treatment for i... |
| 09.03.2021 |
Ventyx Biosciences Takes $114M
| Encinitas-based Ventyx Biosciences, a developer of immune modulators to treat inflammatory diseases and autoimmune disorders, said this morning that it has raised $114M in an equity funding round. The funding was led by venBio Partners, and... |
